Catalog No.S4723 Synonyms: L-Epicatechin, (-)-Epicatechol
Molecular Weight(MW): 290.27
(−)Epicatechin is a flavonoid present in cocoa, green tea and red wine. It is a strong antioxidant, has insulin mimic action and improves heart health.
Purity & Quality Control
Choose Selective ROS Inhibitors
|Description||(−)Epicatechin is a flavonoid present in cocoa, green tea and red wine. It is a strong antioxidant, has insulin mimic action and improves heart health.|
(-)-Epicatechin stimulates mitochondrial respiration and oxygen consumption in Panc-1 cells. Human normal fibroblasts are not affected. (-)-Epicatechin sensitizes Panc-1, U87, and MIA PaCa-2 cells with an average radiation enhancement factor (REF) of 1.7, 1.5, and 1.2, respectively. (-)-Epicatechin does not sensitize normal fibroblast cells to ionizing radiation with a REF of 0.9, suggesting cancer cell selectivity. (-)-Epicatechin enhances Chk2 phosphorylation and p21 induction when combined with radiation in cancer, but not normal cells.
|In vivo||Aging has deleterious effects on modulators of muscle growth/differentiation, the consumption of modest amounts of the flavanol (−)-epicatechin can partially reverse these changes. In mice, myostatin and senescence-associated β-galactosidase levels increase with aging, while those of follistatin and Myf5 decrease. (−)-Epicatechin decreases myostatin and β-galactosidase and increases levels of markers of muscle growth. In humans, myostatin and β-galactosidase increase with aging while follistatin, MyoD and myogenin decrease. Treatment for 7 days with (−)-epicatechin increases hand grip strength and the ratio of plasma follistatin/myostatin. Low-dose (−)-epicatechin treatment resulted in significant increases in skeletal muscle capillarity, mitochondrial biogenesis, and oxidative enzyme activity, which corresponded to lower muscle fatigue and higher endurance capacity when compared to the placebo group. (−)-epicatechin may potentially regulate the protein expression between angiogenic and antiangiogenic factors, such as VEGF-A and TSP-1, respectively.|
|In vitro||DMSO||58 mg/mL (199.81 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03236662||Completed||Becker Muscular Dystrophy||Craig McDonald MD|Cardero Therapeutics Inc.|University of California Davis||November 2016||Phase 2|
|NCT01880866||Withdrawn||Pulmonary Arterial Hypertension||University of California San Francisco||July 2013||Phase 1|
|NCT01856868||Recruiting||Becker Muscular Dystrophy||Craig McDonald MD|Cardero Therapeutics Inc.|University of California Davis||May 2013||Phase 1|Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.